ASCO 2019 day three
Exclusive live coverage from day three of the American Society of Clinical Oncology’s annual meeting in Chicago.
• To view all of our coverage from the preeminent cancer event, produced in association with Kantar Health, as well as additional content, visit the Spotlight on ASCO 2019 and the future of oncology
Key highlights for Sunday include:
- AstraZeneca/Merck & Co will provide one of the highlights of Sunday at ASCO, with data from the phase 3 POLO trial as a maintenance treatment in metastatic pancreatic cancer with germline BRCA mutation. This will flesh out a top-line positive result announced earlier this year.
- Also on Sunday, Roche will present early data from its “tumour agnostic” drug entrectinib in children with recurrent or refractory solid tumours, including central nervous system tumours.
View the live coverage from day three at ASCO 2019 below (the live blog may take a few seconds to load) and we will also have live coverage from day four at ASCO: